Tfe3 mrq37

Manufactured by Cell Marque

Sourced in United States

TFE3 (MRQ37) is an immunohistochemistry antibody product offered by Cell Marque. It is designed for the detection of the TFE3 protein in formalin-fixed, paraffin-embedded tissue samples.

Automatically generated - may contain errors

Lab products found in correlation

Hmb45, by Agilent Technologies (1 mentions) Bond 3 automated system, by Leica (1 mentions) Ck7 ov tl 12 30, by Agilent Technologies (1 mentions) Ventana discovery system, by Roche (1 mentions) Cd10 56c6, by Agilent Technologies (1 mentions) Dako automated system, by Agilent Technologies (1 mentions) P 4ebp1, by Cell Signaling Technology (1 mentions) Benchmark xt, by Roche (1 mentions) Microsystems plus slides, by Leica (1 mentions)

Spelling variants of this product

MRQ37 (4 citations)

3 protocols using tfe3 mrq37

Comprehensive Immunohistochemical Profiling of FFPE Tissues

Check if the same lab product or an alternative is used in the 5 most similar protocols

Immunohistochemistry was conducted using 5 μm formalin-fixed paraffin-embedded (FFPE) whole tissue sections. Staining for common markers including Pax8 (Proteintech, 1:100), CK7 (OV-TL 12/30, DAKO, 1:800), CK20 (Ks20.8, DAKO, 1:1600), CD117 (Cat# A4502, DAKO, 1:1000), TFE3 (MRQ37, Cell Marque), HMB45 (HMB45, DAKO, 1:100), and Melan A (A103, Ventana) was performed using a BenchMark automated system (Roche). Staining for cathepsin-K (3F9, ABCAM, 1:5000) and FH (J13, Santa Cruz, 1:2500) was accomplished using a Bond III automated system (Leica). Staining for SDHB (21A11, Abcam, 1: 100), phospho-S6 (Ser235/236) (D57.2.2E, Cell Signaling Technology, 1:100), and phospho-4E-BP1 (Thr37/46) (236B4, Cell Signaling Technology, 1:400) was performed using an automated Ventana Discovery system (Roche). For CK7 and CK20 staining, the result was interpreted as “negative” if no or rare (<5%) cells staining positive. Immunostaining scores (H-scores) for phospho-S6 and phospho-4E-BP1 were determined as [H= intensity (0–3) x percentage of positive cells (1–100)].

Chen Y.B., Mirsadraei L., Jayakumaran G., Al-Ahmadie H.A., Fine S.W., Gopalan A., Sirintrapun S.J., Tickoo S.K, & Reuter V.E. (2019). Somatic Mutations of TSC2 or MTOR Characterize a Morphologically Distinct Subset of Sporadic Renal Cell Carcinoma with Eosinophilic and Vacuolated Cytoplasm. The American journal of surgical pathology, 43(1), 121-131.

+ Open protocol

+ Expand

Immunohistochemical Profiling of Tumor Markers

Check if the same lab product or an alternative is used in the 5 most similar protocols

IHC analysis was performed on representative 3–5 μm formalin-fixed paraffin-embedded (FFPE) whole tumor tissue sections. Staining for routinely used markers including Pax8 (10336-1-A P, 1:1000; Proteintech), CA9 (11071-1-AP, 1:100; Thermo Fisher), CD10 (56C6, 1:40; Dako), CK7 (M7018- OV-TL 12/30, 1:100; Dako), CK20 (7019-Ks20.8, 1:50; Dako), CD117 (A4502, 1:700; Dako), Melan A (7196-A103, 1;200; Dako), cathepsin-K (37259-3F9, 1:100; Abcam), FH (100743-J13, 1:1500; Santa Cruz), SDHB (14714-21A11, 1:100; Abcam), TFE3 (MRQ-37, 1:200; Cell Marque), TFEB (166736, 1:100; Santa Cruz), vimentin (M0725, 1:75; Dako), phospho-S6 (Ser240/244) (p-S6) (5364-D68F8, 1:300; Cell Signaling Technology) and phospho-4E-BP1 (Thr37/46) (p-4EBP1) (236B4, 1:800; Cell Signaling Technology) was performed using a Dako automated system (Agilent).
Immunoreactivity was interpreted as “negative” if < 5% tumor cells stained positively. P-S6 and p-4EBP1 expression was determined based on the percentage of tumor cells staining positive and the intensity of expression, which were multiplied.

Kapur P., Gao M., Zhong H., Chintalapati S., Mitui M., Barnes S., Zhou Q., Miyata J., Carrillo D., Malladi V., Rakheja D., Pedrosa I., Xu L., Kinch L, & Brugarolas J. (2021). Germline and sporadic mTOR pathway mutations in low-grade oncocytic tumor of the kidney. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 35(3), 333-343.

+ Open protocol

+ Expand

Immunohistochemical Detection of TFE3 in FFPE

Check if the same lab product or an alternative is used in the 5 most similar protocols

TMA paraffin blocks were cut at 4 μm and mounted on positively charged slides (Leica Microsystems plus slides, Menzel, Braunschweig, Germany). Immunostaining was performed in an automated immunostainer (BenchMark XT, Ventana ® Medical Systems Inc., Tucson, AZ, USA). Sections were deparaffinised in xylene and rehydrated. Pre-treatment was done using a prediluted cell conditioning solution (CC1) for 60 min. TFE3-MRQ-37 (Cell Marque, Sierra College Blvd, Rocklin, CA 95677, USA) primary antibody was incubated at 37•C for 16 minutes with TMA sections. The Ventana ® I-view DAB detection kit was used according to the manufacturer's instructions. Subsequently, slides were washed, counterstained with Mayer's haematoxylin, and mounted. Negative control tissue (by substitution of primary antibody with Tris-buffered saline) and positive control tissue were included.

Al-Maghrabi J., Mufti S, & Gomaa W. (2018). The incidence of renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion in Saudi adult patients with renal cancer: a retrospective tissue microarray analysis. Polish journal of pathology : official journal of the Polish Society of Pathologists, 69(4).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!